<DOC>
	<DOCNO>NCT01126086</DOCNO>
	<brief_summary>Primary Objective : - To study effect mild moderate hepatic impairment pharmacokinetics otamixaban . Secondary Objective : - To assess pharmacodynamic effect otamixaban subject mild moderate hepatic impairment match subject normal hepatic function .</brief_summary>
	<brief_title>Pharmacokinetic , Pharmacodynamic Tolerability Study Otamixaban Patients With Mild Moderate Hepatic Impairment</brief_title>
	<detailed_description>The duration part study one subject 28 day screen , 1 day treatment , 5 day unit ( Day -1 Day 4 ) 8 11 day follow-up start infusion .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Otamixaban</mesh_term>
	<criteria>Inclusion criterion : Subjects hepatic impairment : Body weight 50.0 kg 115.0 kg inclusive male , 40.0 kg 100.0 kg inclusive female , Body Mass Index 18.0 34.9 kg/m2 inclusive Stable chronic liver disease assess medical history , physical examination , laboratory value Vital sign , cardiac function laboratory parameter within acceptable range subject hepatic impairment If female , subject must use double contraception method , except sterilize 3 month postmenopausal Patients hepatic impairment match healthy subject define healthy physical examination , medical history laboratory finding match patient respect age , gender , body weight . Inclusion/exclusion criterion healthy subject may differ slightly list patient define study protocol Exclusion criterion : Uncontrolled clinically relevant cardiovascular , pulmonary , gastrointestinal , metabolic , hematological , neurological , psychiatric , systemic , ocular , gynecologic ( female ) , infectious disease , sign acute illness Creatinine level upper limit normal Hepatocarcinoma Acute hepatitis Hepatic encephalopathy grade 2 , 3 4 History presence drug alcohol abuse within two year inclusion Smoking 15 cigarette equivalent per day , unable refrain smoke institutionalization Any significant change chronic treatment medication within 14 day inclusion The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>